  KT-579 Overview
  Potential First-in-Class Opportunity with Oral Small Molecule Profile


                                • IRF5 has the potential to • Human and mouse         • IRF5 degradation in vivo   • KT-579 fully
              KT-579 is           be the first broad anti-    genetics de-risk safety leads to robust cytokine       degrades IRF5
              a first-in-class, inflammatory to affect        and clinical indications inhibition and in vivo        across multiple
              potent,             immune dysregulation                                  efficacy in models of        preclinical species
              selective, oral while sparing normal cell                                 lupus and RA superior to     with a favorable
              IRF5 degrader function                                                    approved drugs in the        safety profile
                                                                                        space



      OPPORTUNITY
                                                            • Large potential for oral degrader with      Potential to expand access
• Over 10M potential    • WW market for SLE, LN, RA,                                                      to oral systemic advanced
                          IBD alone was >$45B in 2023         biologics-like activity to block
  patient impact1                                                                                         therapies in many diseases
                          and projected to grow to            established pro-inflammatory
                                                              pathways, IFN response, & key               with no or suboptimal oral
                          >$55B by 20291                                                                  options
                                                              pathogenic cell types


                                                                          UPCOMING                  • Phase 1 HV start: Q1 2026
       STATUS          • IND-enabling studies completed                   MILESTONES                • Phase 1 HV data: 2H 2026

                                                                                                                                     37
